How do we ensure cost-effectiveness?

Achieving cost-effectiveness in the development and delivery of our Alzheimer's treatment is central to LETHE's mission. We ensure broad accessibility while maintaining financial sustainability through strategic partnerships, streamlined production processes, and innovative distribution methods.

Our strategies for cost-effectiveness include:

• To minimize overhead costs while maximizing accessibility, our therapeutic delivery model relies on mobile treatment units. These vans, equipped with refrigeration and essential medical facilities, will bring treatment directly to patients, eliminating the need for large, fixed infrastructure. Starting from Patras, Greece, the location of our University where this project originated, we will gradually expand by adding more vans instead of opening additional physical locations. This flexible approach significantly reduces the costs associated with setting up new clinics, and we will also offer our treatment to clinics that can modify their spaces accordingly.


• By purchasing essential components such as viral vectors and miRNA materials in bulk, we can benefit from economies of scale, reducing procurement costs. This strategy ensures that we can produce at lower costs, making our therapy more affordable to a larger population.


• To further enhance cost-efficiency, we will collaborate with specialized companies to supply induced pluripotent stem cells (iPSCs) rather than producing them in-house, particularly in the early stages. This approach not only minimizes the risk of mishandling due to human error but also significantly reduces operational costs. By focusing on partnerships, we can allocate resources to other critical areas like development and scaling.


• In addition to iPSCs, we have already, in our initial stages, established partnerships with companies that provided us with Exosome isolation kits (e.g., ExoPrep) for free. Adhering to contractual agreements with these companies will allow us to keep costs manageable by reducing expenses for essential components. We also plan to partner with firms for plasmid production to further drive down costs.


• Moreover, by purchasing essential components and materials in bulk, we benefit from economies of scale, further reducing procurement costs. This ensures that we can produce at lower costs and make our therapy accessible to a larger population.


• As our start-up achieves greater profitability, we plan to incorporate automated systems into our production and quality control processes, reducing labor costs and minimizing human error. Standardizing the manufacturing process ensures consistent product quality while lowering overall operational costs. This approach helps streamline production and allows for scalable growth as demand increases.